China Aoxing Pharmaceutical Company, Inc. announced that its Chinese subsidiary, Hebei Aoxing Pharmaceutical Group, has received GMP (Good Manufacturing Practices) certification for its Naloxone raw materials workshop from the State Food and Food Administration (SFDA) of the People's Republic of China.

Hebei Aoxing expects to begin production of its Naloxone raw materials on December 1, 2006. The Company initially received the SFDA license (H20064846) to manufacture Naloxone raw materials in April of 2006. As is the procedure in China, even after a company has obtained the SFDA license to manufacture drugs, it must pass GMP inspections and verifications of its facilities before actual production can begin.

Naloxone is a drug clinically used to treat illnesses related to opioid overdose, shock, and alcohol poisoning. The drug is synthesized from thebaine, which in the US is classified as a Schedule II drug by the Controlled Substance Act. As such, the supply of Naloxone raw materials is completely controlled by the central government in China. The government restricts the manufacture and sale of the Naloxone to only three companies, including Hebei Aoxing.

Hebei Aoxing Pharmaceutical Group is a corporation organized under the laws of the People's Republic of China that has developed a patented manufacturing process for a variety of generic analgesic drugs, including Oxycodone, Pholcodine, Naloxone, and Tilidine.

Hebei Aoxing is one of only a handful of companies in China to be granted the license to manufacture these drugs and is working closely with the Chinese government to assure their availability throughout China. China Aoxing Pharmaceutical Company acquired Hebei Aoxing in a reverse merger transaction in April of 2006.

Source:佚名